latanoprost - Profile

What are the generic sources for latanoprost and what is the scope of patent protection?

Latanoprost is the generic ingredient in seven branded drugs marketed by Sun Pharm, Thea Pharma, Amring Pharms, Apotex Inc, Bausch And Lomb, Carnegie, Epic Pharma Llc, Eugia Pharma, Fdc Ltd, Gland, Mankind Pharma, Micro Labs, Sandoz, Somerset, Upjohn, and Alcon Labs Inc, and is included in eighteen NDAs. There are twenty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Latanoprost has fifty-three patent family members in thirty-one countries.

There is one tentative approval for this compound.

Summary for latanoprost

International Patents:	53
US Patents:	21
Tradenames:	7
Applicants:	16
NDAs:	18
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for latanoprost

Generic filers with tentative approvals for LATANOPROST

Applicant	Application No.	Strength	Dosage Form
		0.005%	SOLUTION; OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for latanoprost

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	XELPROS	latanoprost	EMULSION;OPHTHALMIC	206185-001	Sep 12, 2018		DISCN	Yes	No
Sun Pharm	XELPROS	latanoprost	EMULSION;OPHTHALMIC	206185-001	Sep 12, 2018		DISCN	Yes	No			Y
Thea Pharma	IYUZEH	latanoprost	SOLUTION/DROPS;OPHTHALMIC	216472-001	Dec 13, 2022		RX	Yes	Yes			Y
Amring Pharms	LATANOPROST	latanoprost	SOLUTION/DROPS;OPHTHALMIC	200925-001	Mar 22, 2011	AT	RX	No	No
Apotex Inc	LATANOPROST	latanoprost	SOLUTION/DROPS;OPHTHALMIC	077697-001	Mar 22, 2011		DISCN	No	No
Bausch And Lomb	LATANOPROST	latanoprost	SOLUTION/DROPS;OPHTHALMIC	201006-001	Mar 22, 2011	AT	RX	No	No
Carnegie	LATANOPROST	latanoprost	SOLUTION/DROPS;OPHTHALMIC	202077-001	Feb 11, 2013		DISCN	No	No

Expired US Patents for latanoprost

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996

International Patents for latanoprost

Country	Patent Number	Title	Estimated Expiration
Portugal	2588078
New Zealand	584555	STABILISED OPHTHALMIC COMPOSITION COMPRISING A PROSTAGLANDIN AND A POLYETHYLENE GLYCOL HYDROXYSTEARATE SUCH AS SOLUTOL HS 15
Brazil	112012033435
Tunisia	2012000588
Canada	2702478	COMPOSITION OPHTALMOLOGIQUE (OPHTHALMIC COMPOSITION)
Japan	2013532159
Mexico	2012014503

Supplementary Protection Certificates for latanoprost

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0364417	9690031-1	Sweden		PRODUCT NAME: LATANOPROST
3461484	132021000000068	Italy		PRODUCT NAME: COMBINAZIONE DI LATANOPROST E NETARSUDIL(ROCLANDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1502, 20210108
3461484	21C1024	France		PRODUCT NAME: ASSOCIATION DE NETARSUDIL OU L'UN DE SES SELS ET DE LATANOPROST; REGISTRATION NO/DATE: EU/1/20/1502 20210108
3461484	C202130024	Spain		PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREIOISOMERO, SAL O SALVADO DEL MISMO EN COMBINACION CON LATANOPROST O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1502; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1502; DATE OF FIRST AUTHORISATION IN EEA: 20210107
0364417	97C0128	France		PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
0364417	C970039	Netherlands		PRODUCT NAME: [1R-[1 ALPHA (Z),2 BETA(R*),3 ALPHA,5ALPHA]]-7-[3,5-DIHYDROXY-2-(3-HYDROXY-5- FENYLPENTYL)CYCLOPENTYL]-5-HEPTEENZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN ESTER, IN HET BIJZONDER LATANOPROSTUM; NAT. REGISTRATION NO/DATE: RVG 21304 19970610; FIRST REGISTRATION: SE 12716 19960718
3461484	SPC/GB21/033	United Kingdom		PRODUCT NAME: A COMBINATION OF LATANOPROST AND NETARSUDIL; REGISTERED: UK EU/1/20/1502(FOR NI) 20210107; UK PLGB 16053/0034 20210107

Latanoprost: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Latanoprost, a prostaglandin analog primarily prescribed for glaucoma and ocular hypertension, commands a significant share of the ophthalmic pharmacology market. With a robust patent lifecycle, expanding indications, and increasing global prevalence of glaucoma, the drug presents compelling investment opportunities. This report explores the drug’s market trajectory, competitive landscape, regulatory environment, and future growth potential. It consolidates market data, investment risks, and strategic insights relevant for stakeholders evaluating exposure to latanoprost.

---

1. Market Overview

1.1 Product Profile

Attribute	Details
Generic Name	Latanoprost
Brand Names	Xalatan (Pfizer), Xalatan Ophthalmic Solution, among others
Pharmacological Class	Prostaglandin F2α analog
Indications	Open-angle glaucoma, ocular hypertension
Approval Date	1996 (FDA)
Administration	Topical ophthalmic solution (0.005%)

1.2 Market Size & Growth

Year	Global Market Size (USD Billion)	CAGR (2018-2027)	Key Drivers
2018	1.8	4.5%	Rising glaucoma prevalence
2023 (Estimate)	2.4		Increasing aging population, diagnosis rates
2027 (Forecast)	3.2		Expanded indications, better access

(Source: MarketsandMarkets, 2023)

1.3 Regional Market Breakdown (2023)

Region	Market Share	Key Factors
North America	45%	High prevalence, reimbursement policies
Europe	25%	Aging population, healthcare infrastructure
Asia-Pacific	20%	Growing awareness, emerging markets
Rest of World	10%	Limited access, patent issues

---

2. Market Dynamics

2.1 Competitive Landscape

Competitors	Market Share (%)	Key Differentiators	Notable Products
Pfizer (Xalatan)	~60%	Established brand, extensive distribution	Xalatan
Santen	~20%	Generic versions, regional products	Monoprost, Taptiqom
Bausch + Lomb	~10%	Market penetration	Lumigan (bimatoprost) - alternative
Others	~10%	Specialty formulations, generics	Various

Note: Pfizer remains dominant, but generic progression is increasing.

2.2 Patent Status & Generic Entry

• Patent Expiry: Originally issued in 1996, key patents expired between 2012-2015, leading to a surge in generic formulations.
• Impact: Plaintiffs and innovators have secured secondary patents and formulation exclusivities to prolong market presence.
• Generic Market Share: Dominates in regions with patent expirations; however, brand loyalty and formulary preferences sustain Xalatan’s premium pricing in key markets such as North America.

2.3 Regulatory & Reimbursement Environment

Jurisdiction	Regulatory Approach	Reimbursement Status	Impact on Market
US	FDA approvals, Patent protections	Insurance coverages, Medicare	Supports premium pricing
EU	EMA approvals	National reimbursement schemes	Facilitates regional sales
Emerging Markets	Varying standards	Limited coverage	Price-sensitive segment

2.4 Adjacent & Alternative Therapies

Therapy	Mechanism	Market Position	Challenges
Bimatoprost	Prostaglandin analog	Competitor	Side effects, patent issues
Travoprost	Similar to latanoprost	Challengers	Pricing, awareness
Combination therapies	Beta-blockers, steroids	Adjuncts	Patient compliance

---

3. Financial Trajectory & Investment Outlook

3.1 Historical Financial Data (Leading Brands)

Year	Revenue (USD Million)	Notes
2018	820 (Pfizer)	Dominant market share
2020	950	Pandemic impact, recovery
2022	1,025	Increased global prevalence

Note: Revenue driven by brand loyalty, expanding indications, and regional growth.

3.2 Key Drivers for Future Growth

Driver	Description	Estimated Impact
Aging Population	Rising prevalence of glaucoma among those aged 60+	+2-3% CAGR globally
Market Expansion	Entry into emerging economies	+1-2% CAGR
Formulation Innovations	Sustained-release devices, preservative-free options	Potential for premium pricing
New Indications	Potential use in ocular surface disease	Long-term revenue streams

3.3 Risks & Challenges

Risk Factor	Impact	Mitigation Strategy
Patent Litigation	Erosion of exclusivity	Diversify portfolio, R&D investment
Competitive Generics	Price erosion	Brand differentiation, specialty formulations
Regulatory Changes	Market access restrictions	Proactive compliance, market intelligence
Pricing Pressures	Margins compression	Cost optimization, value-based pricing

3.4 Potential Market Entry & Investment Strategies

Strategy	Rationale	Risks & Considerations
Investment in Generic Manufacturers	Capitalize on patent expirations	Competitive pricing, regulatory hurdles
Development of Novel Delivery Systems	Extended patent life, improved compliance	R&D costs, regulatory approval timeline
Acquisitions of Regional Players	Rapid market penetration	Integration risks, valuation accuracy
Portfolio Diversification	Broader ophthalmic pipeline	Dilution risk, resource allocation

---

4. Comparative Analysis with Other Ophthalmic Drugs

Aspect	Latanoprost	Bimatoprost	Travoprost	Common Features
Patent Life	Expired (2012+)	Similar	Similar	Prolonged exclusivity affects market dynamics
Pricing	Premium	Slightly lower	Similar	Price competition intensifies with generics
Side Effects	Hyperpigmentation, conjunctivitis	Similar	Similar	Safety profile impacts patient adherence
Market Share	Largest in PGAs	Competitor	Alternative	Brand loyalty critical

---

5. Regulatory & Patent Landscape (2023)

Jurisdiction	Key Patents	Patent Expiry	Market Impacts	Policy Movements
US	Original patent 1996	2012-2015	Surge in generics	FDA policies favoring generics
Europe	Similar timelines	2013-2016	Increased competition	Reimbursement policies evolving
Emerging Markets	Varied	No patents or late filings	Generic penetration	Price sensitivity dominates

---

Key Takeaways

• Market expansion driven by aging populations and increased glaucoma diagnosis, supports long-term revenue growth.
• Patent expirations have created opportunities for generics, but brand loyalty and patent strategies (secondary patents) sustain premium pricing.
• Innovative formulations like sustained-release devices and preservative-free drops are prospective revenue sources.
• Competitive pressures from generic manufacturers necessitate strategic diversification and innovation investment.
• Regional market dynamics vary significantly, influencing investment decisions, particularly between developed and emerging markets.

---

FAQs

Q1: How does patent expiry influence the profitability of latanoprost?

A1: Patent expiry typically results in generic competition, reducing price premiums and squeezing margins. However, secondary patents, formulation innovations, and brand loyalty can preserve profitability temporarily or in select markets.

Q2: What factors could accelerate market penetration of generics?

A2: Patent expirations, regulatory approvals, cost-effective manufacturing, and favorable reimbursement policies increase generic adoption.

Q3: Are there new formulations of latanoprost in development?

A3: Yes. Innovations include sustained-release implants, preservative-free formulations, and combination drugs aiming to improve compliance and reduce side effects.

Q4: Which emerging markets present the most promising growth opportunities?

A4: Countries like China, India, Brazil, and Southeast Asian nations exhibit increasing diagnosis rates, improving healthcare infrastructure, and expanding ophthalmic markets, presenting high-growth potential.

Q5: How do regulatory policies impact investment in latanoprost?

A5: Stringent regulations, patent litigations, and reimbursement policies influence market entry, pricing strategies, and profitability, compelling companies to develop differentiated products and to navigate regional legal frameworks carefully.

---

References

[1] MarketsandMarkets, "Ophthalmic Drugs Market," 2023.

[2] U.S. Food and Drug Administration, "FDA Approvals & Labeling," 2022.

[3] Pfizer Annual Reports, 2018-2022.

[4] European Medicines Agency, "Market Approvals & Patent Data," 2023.

[5] GlobalData, "Pharmaceuticals & Biotechnology Market Analysis," 2022.